China In-Licensing Crossroads: Zai Lab, Everest March Towards Market But BioNova Returns Rights

 
• By Dexter Jie Yan
  
in-licensing at a crossroads
Amid funding crunch, Chinese in-licensing players reach crossroads toward commercialization • Source: Shutterstock

More from China

More from Focus On Asia